Cogstate Ltd (AU:CGS)
ASX:CGS
Want to see AU:CGS full AI Analyst Report?
CGS Stock Chart & Stats
AU$2.53
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.53
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$1.35 - AU$2.97
Previous CloseN/A
Volume30.50K
Average Volume (3M)355.93K
Market Cap
AU$465.48M
Enterprise ValueAU$314.05M
Total Cash (Recent Filing)AU$34.07M
Total Debt (Recent Filing)AU$716.74K
Price to Earnings (P/E)29.9
Beta0.16
Next Earnings
Aug 18, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield0.88%
Share Statistics
EPS (TTM)0.06
Shares Outstanding169,884,350
10 Day Avg. Volume327,690
30 Day Avg. Volume355,934
Financial Highlights & Ratios
PEG Ratio1.95
Price to Book (P/B)6.26
Price to Sales (P/S)9.00
P/FCF Ratio35.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.18Price Target Upside25.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.06
Revenue Forecast (FY)AU$59.12M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity & No DebtA cash balance of $34.1M and zero debt provides durable financial flexibility to absorb clinical trial timing volatility, fund technology and AI investments, and support channel expansion without needing external financing, strengthening strategic optionality over the next 2–6 months.
High And Sustainable MarginsGross margin above 60% and a 20% net margin reflect scalable cognitive assessment software and high-value services. These unit economics support durable profitability as trial volumes scale, allowing operating leverage to convert backlog into sustained earnings once revenue timing normalises.
Forward Visibility From Backlog & ContractsA growing $92.3M clinical-trial backlog and rising contracted revenue give meaningful medium-term revenue visibility. This de-risks near-term performance, supports planned margin recovery in H2, and underpins continued targeted investment in delivery capacity and channel partnerships.
Bears Say
Revenue And FCF WeaknessA steep revenue decline and halved free cash flow indicate structural sensitivity to study activity and timing. Persistently weaker cash generation limits reinvestment capacity and increases reliance on backlog conversion to restore normalised growth and fund strategic initiatives over the coming months.
Concentration Risk In Core IndicationDependence on large Alzheimer’s presymptomatic trials creates lumpy revenue cycles: when big trials pause or conclude, top-line and utilization fall sharply. This structural concentration elevates volatility and makes smoothing revenue growth dependent on successful diversification into other CNS and real‑world indications.
Revenue Recognition & Mix VolatilityA shifting mix toward license fees and Phase IV/real‑world evidence contracts introduces timing and recognition variability. This structural mix volatility complicates forecasting, can depress in‑period yields, and may transiently pressure reported margins despite healthy underlying demand.
Cogstate Ltd News
CGS FAQ
What was Cogstate Ltd’s price range in the past 12 months?
Cogstate Ltd lowest share price was AU$1.35 and its highest was AU$2.97 in the past 12 months.
What is Cogstate Ltd’s market cap?
Cogstate Ltd’s market cap is AU$465.48M.
When is Cogstate Ltd’s upcoming earnings report date?
Cogstate Ltd’s upcoming earnings report date is Aug 18, 2026 which is in 65 days.
How were Cogstate Ltd’s earnings last quarter?
Cogstate Ltd released its earnings results on Feb 18, 2026. The company reported AU$0.036 earnings per share for the quarter, beating the consensus estimate of AU$0.029 by AU$0.007.
Is Cogstate Ltd overvalued?
According to Wall Street analysts Cogstate Ltd’s price is currently Undervalued.
Does Cogstate Ltd pay dividends?
Cogstate Ltd pays a Notavailable dividend of AU$0.02 which represents an annual dividend yield of 0.88%. See more information on Cogstate Ltd dividends here
What is Cogstate Ltd’s EPS estimate?
Cogstate Ltd’s EPS estimate is 0.05.
How many shares outstanding does Cogstate Ltd have?
Cogstate Ltd has 169,884,350 shares outstanding.
What happened to Cogstate Ltd’s price movement after its last earnings report?
Cogstate Ltd reported an EPS of AU$0.036 in its last earnings report, beating expectations of AU$0.029. Following the earnings report the stock price went up 8.716%.
Which hedge fund is a major shareholder of Cogstate Ltd?
Currently, no hedge funds are holding shares in AU:CGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogstate Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.18 (25.49% Upside)
AU$3.18 (25.49% Upside)
Insider Transactions
Bought Shares
Worth AU$10.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
140.24%
12-Months-Change
Fundamentals
Return on Equity
29.05%
Trailing 12-Months
Asset Growth
12.30%
Trailing 12-Months
Company Description
Cogstate Ltd
Melbourne, Australia-based Cogstate Limited, established in 1999, is a neuroscience technology company specializing in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Its comprehensive suite of cognitive services includes project and data management, scientific consulting, statistical analysis, procurement of assessment scales, rater training, and monitoring solutions. The company operates through two distinct divisions. The Clinical Trials segment delivers technology and support services designed to measure the impact of diseases, pharmaceuticals, medical devices, or other interventions on human participants in clinical studies, primarily serving pharmaceutical and biotechnology clients. Concurrently, its Healthcare segment offers Cognigram, a system facilitating regular and standardized testing to assist primary care physicians and hospitals in the early identification of cognitive decline. By June 30, 2022, Cogstate had participated in an estimated 1,800 academic research initiatives.
CGS Company Deck
CGS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and forward visibility: record new trial starts, a 105% jump in sales contracts, solid YoY revenue/backlog growth, expanding channel partnerships, and a healthy cash balance. Short‑term margin pressure and a $0.5M doubtful debt provision were acknowledged, largely driven by deliberate investments in delivery capacity, timing of contract recognition and one‑off adjustments. Management expects margins to recover in H2 as contracted revenue converts and maintains a clear strategy of diversification and technology investment to sustain medium‑term growth.View all AU:CGS earnings summariesCGS Stock 12 Month Forecast
Average Price Target
AU$3.18
▲(25.49% Upside)
Technical Analysis
Tali Digital
―
Opyl Ltd.
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---